TrichosanatineCAS# 169626-16-8 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 169626-16-8 | SDF | Download SDF |
PubChem ID | 134715057 | Appearance | Powder |
Formula | C27H28N2O4 | M.Wt | 444.53 |
Type of Compound | Alkaloids | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | [2-hydroxy-3-(1-phenylethylideneamino)propyl] (2S)-2-benzamido-3-phenylpropanoate | ||
SMILES | CC(=NCC(COC(=O)C(CC1=CC=CC=C1)NC(=O)C2=CC=CC=C2)O)C3=CC=CC=C3 | ||
Standard InChIKey | YKOLPGPCLASMMB-BBMPLOMVSA-N | ||
Standard InChI | InChI=1S/C27H28N2O4/c1-20(22-13-7-3-8-14-22)28-18-24(30)19-33-27(32)25(17-21-11-5-2-6-12-21)29-26(31)23-15-9-4-10-16-23/h2-16,24-25,30H,17-19H2,1H3,(H,29,31)/t24?,25-/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | 1. Trichosanatine and squamosamide, as potential candidates as lead compounds for further study in drug development process with the PP2A- α protein. 2. Trichosanatine can alleviate oxidized low-density lipoprotein induced endothelial cells injury via inhibiting the LOX-1/p38 MAPK pathway. |
Targets | LOX | p38MAPK | ROS | LDL | MMP(e.g.TIMP) |
Trichosanatine Dilution Calculator
Trichosanatine Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.2496 mL | 11.2478 mL | 22.4957 mL | 44.9913 mL | 56.2392 mL |
5 mM | 0.4499 mL | 2.2496 mL | 4.4991 mL | 8.9983 mL | 11.2478 mL |
10 mM | 0.225 mL | 1.1248 mL | 2.2496 mL | 4.4991 mL | 5.6239 mL |
50 mM | 0.045 mL | 0.225 mL | 0.4499 mL | 0.8998 mL | 1.1248 mL |
100 mM | 0.0225 mL | 0.1125 mL | 0.225 mL | 0.4499 mL | 0.5624 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Odoratone
Catalog No.:BCN1105
CAS No.:16962-90-6
- Celecoxib
Catalog No.:BCC1099
CAS No.:169590-42-5
- Deracoxib
Catalog No.:BCC4108
CAS No.:169590-41-4
- Floricaline
Catalog No.:BCN2104
CAS No.:16958-32-0
- Floridanine
Catalog No.:BCN2103
CAS No.:16958-31-9
- Florosenine
Catalog No.:BCN2108
CAS No.:16958-30-8
- Otosenine
Catalog No.:BCN2107
CAS No.:16958-29-5
- Fmoc-Ala(4-pyridyl)-OH
Catalog No.:BCC3327
CAS No.:169555-95-7
- IRL-2500
Catalog No.:BCC7192
CAS No.:169545-27-1
- Protostemotinine
Catalog No.:BCN8314
CAS No.:169534-85-4
- RS 17053 hydrochloride
Catalog No.:BCC6874
CAS No.:169505-93-5
- Boc-N-Me-Ala-OH
Catalog No.:BCC3209
CAS No.:16948-16-6
- Isodonal
Catalog No.:BCN3390
CAS No.:16964-56-0
- Z-Thr(tBu)-OH.DCHA
Catalog No.:BCC2565
CAS No.:16966-07-7
- Ro 60-0175 fumarate
Catalog No.:BCC7196
CAS No.:169675-09-6
- Angelol K
Catalog No.:BCN8142
CAS No.:169736-93-0
- Dibutyryl-cAMP, sodium salt
Catalog No.:BCC8079
CAS No.:16980-89-5
- Mesuol
Catalog No.:BCN6583
CAS No.:16981-20-7
- Iso-cuparenal
Catalog No.:BCN7350
CAS No.:16982-01-7
- LY 333531 hydrochloride
Catalog No.:BCC7969
CAS No.:169939-93-9
- Reserpine hydrochloride
Catalog No.:BCC4279
CAS No.:16994-56-2
- Bufarenogin
Catalog No.:BCN2297
CAS No.:17008-65-0
- Pseudobufarenogin
Catalog No.:BCN8234
CAS No.:17008-69-4
- Alvimopan dihydrate
Catalog No.:BCC1348
CAS No.:170098-38-1
Trichosanatine alleviates oxidized low-density lipoprotein induced endothelial cells injury via inhibiting the LOX-1/p38 MAPK pathway.[Pubmed:28078016]
Am J Transl Res. 2016 Dec 15;8(12):5455-5464. eCollection 2016.
The LOX-1/p38 mitogen-activated protein kinase (MAPK) pathway has been proved to participate in the endothelial dysfunction in atherosclerosis. Trichosanatineis is an active compound isolated from the peel of Trichosanthes kirilowii. This study aims to determine whether Trichosanatine prevents the oxidized low-density lipoprotein (ox-LDL)-induced insult through inhibition of the LOX-1/p38 MAPK pathway in HUVECs. HUVECs were treated with 150 mg/ml ox-LDL for 24 h to establish an ox-LDL-induced endothelial injury model. Cell viability, mitochondrial membrane potential (MMP), apoptosis, reactive oxygen species (ROS) level, LOX-1 and p38 MAPK expression level were measured. The results indicated that HUVECs were pretreated with either 100 mM Trichosanatine or LOX-1 shRNA prior to exposure to ox-LDL for 24 h. Exposure of HUVECs to 150 mg/ml ox-LDL for 24 h significantly up-regulated the expression levels of LOX-1. The increased expression levels of LOX-1 were markedly attenuated by pretreatment with 100 mM Trichosanatine. In addition, the ox-LDL-induced increase in phosphorylated (p) p38 MAPK expression was ameliorated by pretreatment with LOX-1 shRNA. Pretreatment of HUVECs with either Trichosanatine or LOX-1 shRNA before exposure to ox-LDL significantly inhibited the ox-LDL-induced injuries, as evidenced by an increase in cell viability, a decrease in apoptotic cells, a ROS generation and a loss of MMP. In conclusion, we have demonstrated for the first time that the LOX-1/p38 MAPK pathway contributes to the ox-LDL-induced injury in HUVECs. Meanwhile, the Trichosanatine protects the HUVECs against ox-LDL-induced injury at least in part by inhibiting the activated of LOX-1/p38 MAPK pathway.
Potential Protein Phosphatase 2A Agents from Traditional Chinese Medicine against Cancer.[Pubmed:24868239]
Evid Based Complement Alternat Med. 2014;2014:436863.
Protein phosphatase 2A (PP2A) is an important phosphatase which regulates various cellular processes, such as protein synthesis, cell growth, cellular signaling, apoptosis, metabolism, and stress responses. It is a holoenzyme composed of the structural A and catalytic C subunits and a regulatory B subunit. As an environmental toxin, okadaic acid, is a tumor promoter and binds to PP2A catalytic C subunit and the cancer-associated mutations in PP2A structural A subunit in human tumor tissue; PP2A may have tumor-suppressing function. It is a potential drug target in the treatment of cancer. In this study, we screen the TCM compounds in TCM Database@Taiwan to investigate the potent lead compounds as PP2A agent. The results of docking simulation are optimized under dynamic conditions by MD simulations after virtual screening to validate the stability of H-bonds between PP2A- alpha protein and each ligand. The top TCM candidates, Trichosanatine and squamosamide, have potential binding affinities and interactions with key residues Arg89 and Arg214 in the docking simulation. In addition, these interactions were stable under dynamic conditions. Hence, we propose the TCM compounds, Trichosanatine and squamosamide, as potential candidates as lead compounds for further study in drug development process with the PP2A- alpha protein.